



















134Improvement in Oral Chronic Graft-versus-Host
Disease with the Administration of Effervescent
Tablets of Topical Budesonide—An Open, Randomized,
Multicenter Study
Sharon Elad,1 Itai Zeevi,1 J€urgen Finke,2 Michael Koldehoff,3 Rainer Schwerdtfeger,4
Daniel Wolff,5 Ralf Mohrbacher,6 Michael Levitt,1 Roland Greinwald,6 Michael Y. Shapira7Chronic graft-versus-host disease (cGVHD) frequently involves oral tissues. Although the mucosal changes
may be painful and impair oral function, there is currently no topical therapy available for oral cGVHD that
has been proven to work in an evidence-basedmanner. The aims of this study were to (1) assess the response
of patients with oral cGVHD to various doses of a new topical budesonide formulation; (2) evaluate the ef-
ficacy and safety of the new topical budesonide formulation in these patients. An open, randomized, multi-
center phase II pilot study with 4 treatment arms differing in application frequency and duration was
performed. Response to treatment was scored by the clinician and patient using several scales. Oral cGVHD
improved in all patients, with a median reduction of 70%. Pain reduction was similar in all study arms. The rate
of objective improvement (defined as $50%) was not significantly different among the 4 study arms. The
safety profile was satisfactory. Topical budesonide mouthwash (3 mg/10 mL) improved oral cGVHD in all pa-
tients when applied for 5 or 10 minutes, 2 or 3 times daily. The response was similar in all treatment arms.
Safety analysis supported a dosing schedule of 3 mg of budesonide 3 times a day for 10 minutes.
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Graft-versus-host disease (GVHD) is the most
common complication of allogeneic hematopoietic
stem cell transplantation (HSCT) [1]. In the clinical
setting, GVHD is divided into acuteGVHD (aGVHD)
and chronic (cGVHD) forms, which differ in their
pathogenesis, symptoms, signs, time of onset, and1Department of Oral Medicine, Hebrew University—
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6/j.bbmt.2011.06.001prognostic significance. The clinical signs and symp-
toms of cGVHD include liver dysfunction, pulmonary
fibrosis, sclerodermatous skin changes, oral and gastro-
intestinal mucosal changes, and a reduced production
of tears and saliva. Chronic GVHD usually develops
after the third month (100 days) post-HSCT [1,2].
Oral involvement is seen in 33% to 75% of patients
who develop aGVHD and in up to 80% of patients
affected by cGVHD [1,3]. Ulcerated and painful
mucosal lesions significantly impede normal eating
habits and nutritional intake, necessitating appropriate
diagnosis and treatment [4].
Management of oral cGVHD includes systemic
therapy combined with good oral hygiene and the
use of topical medications. Unfortunately, despite
the clear clinical significance, only a few controlled
trials of systemic treatments for cGVHD assessed
oral outcomes [4,5]. Furthermore, oral cGVHD is
often refractory to systemic therapies, and additional
topical treatment is frequently required. Clearly, in
cases where the only disease manifestation is in the
oral cavity, topical therapy is advantageous because
systemic therapy is associated with numerous side
effects. Topical steroid preparations are the mainstay
of local treatment for cGVHD, but these drugs are
not registered for this indication. In addition,
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tacrolimus alone, or in combination, have been used as
topical therapy in oral cGVHD (reviewed by Meier
et al., 2010) [6]. Other treatment modalities, such as
phototherapy, have been assessed with varying levels
of success [6]. However, current treatment recommen-
dations are based on the clinical experience of respected
authorities or very small controlled trials [6,7] and, as
such, cannot be considered evidence-based. There are
several ongoing clinical trials for the treatment of oral
lesions associated with cGVHD [8].
The high potency of the steroid budesonide, com-
bined with its very low bioavailability when absorbed
through mucosal surfaces, prompted us to select it as
the active component in a new pharmaceutical prepa-
ration for topical application for oral cGVHD.
Because of its previously mentioned properties, bude-
sonide has few systemic side effects and is used in the
management of gut GVHD [9]. The development pro-
gram of this new preparation is ongoing and included
a feasibility study [10], a preclinical safety study in
a suitable animal model (R. Mohrbacher, personal
communication), and a pharmacokinetic study in
healthy individuals and oral cGVHD patients [11].
The current study is the next step in the development
process of this formulation of the drug.
The primary aim of this study was to assess the rate
of objective response of patients with oral cGVHD to
various dosing protocols of the new topical budesonide
formulation. The secondary endpoints of this study
were (1) to assess efficacy of new budesonide formula-
tions using several scores for oral cGVHD, (2) to
evaluate subjective improvement of oral cGVHD fol-
lowing budesonide treatment, and (3) to appraise the
safety of the new budesonide formulation.PATIENTS AND METHODS
Study Design
This study was an open, randomized, multicenter
phase II pilot study with 4 treatment arms (randomiza-
tion 1:1:1:1) as follows:
Arm A: rinse for at least 10 minutes 3 times daily
with a 3-mg budesonide effervescent tablet
dissolved in 10 mL of water (morning/noon/
evening).
Arm B: rinse for 5 minutes 3 times daily with a 3-mg
budesonide effervescent tablet dissolved in 10mL
of water (morning/noon/evening).
Arm C: rinse for at least 10 minutes 2 times daily
with a 3-mg budesonide effervescent tablet
dissolved in 10 mL of water (morning/evening).
Arm D: rinse for 5 minutes 2 times daily with
a 3-mg budesonide effervescent tablet dissolved
in 10 mL of water (morning/evening).Four centers participated in the study: (1) Deutsche
Klinik f€ur Diagnostik, KMT-Zentrum, Wiesbaden,
Germany; (2) Universit€atsklinikum Freiburg, Klinik f.
Innere Medizin, Abteilung f. H€amatologie und Onko-
logie, Freiburg, Germany; (3) Universit€atsklinikum
Essen, Klinik f€ur KMT, Essen, Germany; (4) Hadassah
Ein Kerem Medical Center, Jerusalem, Israel.
The ethics boards of all the participating centers
approved the study (EudraCT number 2005-002754-
22). All patients signed an informed consent form.Inclusion and Exclusion Criteria
Inclusion criteria: (1) 18 to 75 years of age; (2)
symptomatic oral cGVHD of erosive and ulcerative
type, diagnosed based on clinical presentation, evi-
dence of systemic cGVHD, and when needed, oral
mucosal biopsy; (3) oral cGVHD resistant to therapy
(eg, lack of partial response to 4 weeks of systemic
prednisone and/or cyclosporine treatment; (4) modi-
fied Oral Mucosa Rating Scale (mOMRS) [18] of at
least 20 (see below); (5) Karnofsky performance status
score [12] of at least 70; (6) conventional primary treat-
ment dosage unchanged or reduced during the 4 weeks
before the current trial started.
Exclusion criteria: (1) symptomatic oral cGVHD
only presenting as the hyperkeratotic type; (2) active
oral bacterial, viral, or fungal infection; (3) additional
systemic therapy required; (4) second-line treatment
of oral cGVHD with topical steroids (eg, dexametha-
sone, beclomethasone) during the 12 weeks before
the current trial started.
Administration of the following drugs/treatments
was permitted during the trial: (1) prophylaxis against
infection: chlorhexidine 0.2% mouthwash and topical
polyene antifungal agents; chlorhexidine use was lim-
ited to twice daily and, if combined with nystatin,
they were used at least 30 minutes apart; (2) systemic
antiviral prophylaxis, such as acyclovir; (3) systemic an-
tifungal treatment such as fluconazole or voriconazole;
(4) prophylaxis against pneumocystis carinii pneumonia
with trimetoprim/sulfamethoxazole; (5) anti-GVHD
medications if the dose remained unchanged or was
adjusted to plasma concentration 4 weeks before the
study started and during the study; (6) dose reduction
of systemic immunosuppression if there was a remission
of cGVHD.
Administration of the following drugs/treatments
was not permitted during the trial: (1) budesonide
or other corticosteroid-containing drugs, except for
conventional primary treatment of cGVHD (ie, sys-
temic prednisone and/or cyclosporine) started before
the study; (2) second-line treatments for cGVHD:
low-dose total lymphoid irradiation, intraoral
PUVA therapy, extracorporeal photochemotherapy,
thalidomide, pentostatin; (3) CYP3A-inhibitors: for
example, ketoconazole, itraconazole, clarithromycin,
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sporine, tacrolimus/FK506 [dose changes were not
permitted during study]); (4) CYP3A-inducers: for
example, carbamazepine, rifampicin; (5) nifedipine;
(6) macrolide antibiotics except azithromycin; (7) dos-
ages of medications potentially confounding assess-
ment of the inflammatory response (antihistamines,
nonsteroidal anti-inflammatory drugs [NSAIDs], an-
tidepressants) could remain unchanged or be reduced,
but no new medications (or increases in dosages) in
this category were accepted during the study.
Study Schedule and Evaluation Protocol
The 8-week study period included 5 evaluations:
baseline (day 0)/interim visits (days 14, 28, and 42)
and final visit (day 56). Time window for visits was
64 days. Demographics and medical history were re-
corded at baseline. Clinical and laboratory assessments
included: (1) organ staging (scoring) of cGVHD [12];
(2) assessment of severity of oral cGVHD using the
mOMRS (see below), oral cGVHD 5-level scale [10],
WHO toxicity scale gastrointestinal/oral [13], and
Oral Mucositis Assessment Scale (OMAS) [14]; (3) tar-
get organs currently affected by cGVHD (skin, mouth,
eyes, vulva/vaginal, gastrointestinal [GI] tract, liver,
lung, hematopoietic, musculoskeletal) [12]; (4) Kar-
nofsky Performance Status [12]; (5) cultures of oral
lesions for bacterial, fungal, and viral infections; (6) in-
traoral examination to rule out local irritation/dental
trauma; (7) pain assessment—using the WHO toxicity
scale pain and WHO pain ladder [15-17]; (8) detailed
diary listing all medications and a score regarding
eating ability and oral symptoms; (9) blood and
urine sampling for laboratory parameters including
hematology, serum chemistry, and urine strip test;
(10) plasma cortisol levels were measured between 7
and 10 a.m. on each visit beginning on the first day
budesonide mouthwash was administered.
Prophylactic drugs/treatments were permitted
during the trial. For details, see Inclusion and Exclu-
sion Criteria ‘‘Administration of the following drugs/
treatments was permitted during the trial.’’
Modified Oral Mucosa Rating Scale (mOMRS)
Oral assessments were conducted using the
mOMRS [18], which divides the oral cavity into 9
anatomical areas (upper and lower lips, upper and lower
labial mucosa, right and left buccal mucosa, dorsal and
lateroventral aspects of the tongue and soft palate). The
mOMRS is a scale from 0 to 81, with higher scores
indicating more severe findings. The manifestations
of oral cGVHD can be described in terms of the degree
of mucosal erythema (05 normal/no change, 15mild
redness, 2 5 moderate redness, 3 5 severe redness
[color of fresh oxygenated blood]), lichen-type hy-
perkeratosis, and pseudomembrane or ulceration(% surface area: 0 5 none, 1 5 .0, but \25%,
2 5 26%-50% of area, 3 5 .50% of area), and pres-
ence of mucoceles (presence or absence).
We defined an ‘‘objective response’’ as an improve-
ment of at least 50% at the final/withdrawal visit
(compared to baseline) in the mOMRS.
After we initiated our study, the format of the
OMRS used by the NIH was altered; therefore, we
refer to the scale we used as ‘‘modified OMRS.’’
Study Medication
A new formulation of budesonide, a 3-mg efferves-
cent tablet, was developed for this study (Dr. Falk
GmbH, Freiburg, Germany). This preparation targets
oral inflammatory sites and is easier to administer
than formulations used in previous studies, where the
patients had to crush a tablet and dissolve it in water
[10,19]. Administration of the drug was immediately
following a meal. The patients were instructed to
perform oral hygiene (brushing and rinsing), then
place the entire 10 mL of the solution in their
mouths, rinse for the time specified by their treatment
arm (5 or 10 minutes), and then expectorate (not
swallow). They were told not to eat or drink for at
least 1 hour after administration of the study drug.
Patients were not allowed to ingest grapefruit in any
form, including juice.
Statistics
Because the study was exploratory in nature, we
decided that 5 patients per treatment arm were suffi-
cient to give preliminary insight into the effects of
the different treatment regimens, possible major side
effects as well as patient compliance. In addition, the
pooled sample sizes (n 5 10) of the 2 treatments
arms with budesonide 6 mg daily and budesonide
9 mg daily, respectively, provided 80% power to
yield statistical significance using paired t tests with
a 1-sided significance level of 2.5% in cases of intrain-
dividual changes of 10 points on the mOMRS scale at
a standard deviation of 10 points.
For quantitative parameters, relative reductions
(%) between final/withdrawal visit and baseline were
calculated and subjected to descriptive analyses. Cate-
goric variables were presented in frequency tables and
treatment arms were compared using the Fisher exact
test. For ordinal variables, nonparametric measures of
location and dispersion, such as medians and ranges,
were derived supplementally usingmeans and standard
deviations in cases of quantitative parameters. Unless
otherwise stated, Kruskal-Wallis tests were used for
treatment arm comparisons of these variables. All
P values are 2 sided.
Adverse event verbatim descriptions were coded
with MedDRA Version 10.1 (MedDRA[r] the Medical
Dictionary for Regulatory Activities terminology is the
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the auspices of the International Conference on Har-
monization of Technical Requirements for Registra-
tion of Pharmaceuticals for Human Use [ICH]) and
presented in a stratified manner using System Organ
Classes and Preferred Terms. Serum cortisol concen-
trations of all patients with at least 1 measurement
of serum cortisol were averaged per visit. Serum cori-
sol concentrations were compared between visits
using a mixed model with repeated measurements
(2-sided test).
All statistical analyses were performed using SAS
software package V.9.1.3 (SAS Institute, Cary, NC).
A value of P\ .05 was considered significant.RESULTS
Patient Characteristics
Nineteen patients were screened and registered be-
tween 2006 and 2007; however, because of a screening
error, only 18 patients were randomized and treated
with budesonide effervescent tablets. Demographic
data, baseline characteristics, and medical background
are presented in Table 1. Nine patients received oral
prophylactic treatment with amphotericin B.
Two patients discontinued prematurely: 1 patient
in arm B suffered from esophagitis, and 1 patient in
arm D dropped out because of a deterioration of their
cGVHD that required systemic steroids.
The 4 arms did not differ significantly (P. .05) in
any of the scales at baseline (Table 1): mOMRS, fre-
quency distribution of WHO toxicity scale gastroin-
testinal/oral, and OMAS.
All patient diaries were reviewed to assess compli-
ance, which was confirmed.Table 1. Demographics, Medical Background, and Oral cGVHD St
Arm A
No. of Patients 4
Demographics
Gender M:F ratio 4:0
Age Mean (SD), years 35.8 (8.4)
Median (range), years 36.0 (26-45)
Medical background
Time between HSCT and trial Median (range), weeks 272.0 (32-716)




mOMRS Median (range) 34 (23-40)




Grade 2 4 (100%)
Grade 3
OMAS at baseline visit Median (range) 2.0 (1.7-2.0)
No. indicates number; M, male; F, female; SD, standard deviation; GVHD, gra
mOMRS, modified oral mucosal rating scale; OMAS=Oral Mucositis Assessm
*Prednisone/prednisolone.Efficacy Evaluation
All patients improved, that is, the severity of their
oral cGVHD was reduced: A median relative reduc-
tion of 70% for mOMRS and 69% for OMAS was
noted (Table 2). Incidence of objective improvement
was high: A 50% reduction in mOMRS was noted in
61% of the patients. The incidence of improvement
was also high according to the WHO toxicity scale
gastrointestinal/oral (61%) (Table 2).
The mean treatment duration until reaching the
best oral cGVHD status (lowest score) ranged between
5.28 and 6.50 weeks for the 4 scales used (Table 2).
The results of the primary efficacy endpoint
showed that the rate of objective response (more
than 50% compared to baseline) using the mOMRS
was not significantly different among the 4 study
arms (Table 2). The only scale, of the 7 used, that
showed significant differences between the study
arms regarding the response to treatment was ‘‘time
to minimal WHO toxicity gastrointestinal/oral score’’
(Table 2).
Subjective Improvement
There was no difference between the study arms
regarding improvements in any of the subjective
parameters that were scored: pain (various scales), dry-
ness, and sensitivity (Table 3).
Pooling of Subgroups According to Frequency of
Mouthwash Use
Pooling the study arms with the same number of
daily doses (groups A1B and groups C1D) allowed
us to evaluate the importance of the frequency of
mouthwash use. The frequency of mouthwash use
had little impact on the response to treatment,atus at Baseline
Arm B Arm C Arm D Total
5 4 5 18
4:1 3:1 2:3 13:5
44.6 (9.6) 53.3 (14.2) 42.0 (8.2) 43.8 (11.1)
45.0 (34-55) 57.0 (33-66) 40.0 (34-55) 42.0 (26-66)
133.0 (64-349) 181.5 (173-216) 162.0 (59-305) 176.5 (32-716)
4 (80%) 2 (50%) 5 (100%) 15 (83%)
4 (80%) 2 (50%) 5 (100%) 14 (78%)
37 (21-63) 25 (23-26) 24 (20-44) 26 (20-63)
1 (25%) 1 (20%) 2 (11%)
3 (60%) 3 (75%) 3 (60%) 13 (72%)
2 (40%) 1 (20%) 3 (17%)
2.6 (1.0-4.0) 1.8 (0.7-2.0) 1.1 (0.7-2.1) 1.9 (0.7-4.0)
ft-versus-host disease; HSCT, hematopoietic stem cell transplantation;
ent Scale.
Table 2. Response to Treatment
Arm A Arm B Arm C Arm D Total P Value*
Final visit
mOMRS No. of patients with objective response
(i.e., at least 50% reduction)
2/4 (50%) 2/5 (40%) 3/4 (75%) 4/5 (80%) 11/18 (61%) .6355
(Fisher exact test)
No. of patients with any reduction 4/4 (100%) 5/5 (100%) 4/4 (100%) 5/5 (100%) 18/18 (100%)
Median relative reduction (%) (range) 261 (285.0-234.8) 249 (290.5-213.5) 269 (276.0-229.2) 279 (290.0-244.4) 270 (290.5-213.5) .4143
OMAS No. of patients with any reduction 4/4 (100%) 5/5 (100%) 4/4 (100%) 5/5 (100%) 18/18 (100%)
Median relative reduction (%) (range) 248 (272-222) 264 (283-213) 276 (283-272) 280 (2100-263) 269 (2100-213) .0874
WHO toxicity
gastrointestinal/oral
No. of patients with any reduction
(at least 1 step)
1/4 (25%) 3/5 (60%) 3/4 (75%) 4/5 (80%) 11/18 (61%) .4847
(Fisher exact test)
Duration to best efficacy, mean in weeks (SD)
Time to lowest mOMRS score 8.08 (0.22) 4.02 (2.52) 7.58 (1.36) 6.86 (3.12) 6.50 (2.61) .1477
Time to lowest OMAS score 7.25 (1.71) 5.60 (2.67) 7.58 (1.36) 5.56 (2.90) 6.39 (2.32) .5868
Time to lowest WHO toxicity gastrointestinal/oral score 8.08 (0.22) 4.02 (2.56) 7.90 (0.70) 4.42 (2.02) 5.89 (2.52) .0265
Time to lowest oral cGVHD 5-level score 6.65 (2.02) 3.30 (2.85) 6.00 (2.71) 5.60 (2.95) 5.28 (2.78) .3625
OMRS indicates oral mucosal rating scale; cGVHD, chronic graft-versus-host disease.
*Two-sided Kruskal-Wallis test unless otherwise specified.
Table 3. Subjective Parameters and Analgesic Consumption
Arm A Arm B Arm C Arm D Total P Value*
WHO toxicity scale pain No. (%) of patients with any reduction (at least 1 point) 3 (75%) 2 (40%) 2 (50%) 4 (80%) 11 (61%) .6355 (Fisher exact test)
WHO pain ladder No. (%) of patients with any reduction (at least 1 point) 1 (25%) 1 (20%) 0 (0%) 2 (40%) 4 (22%) .8693 (Fisher exact test)
Patient’s subjective description Median in % (range) of
relative reduction:
Mouth dryness 231 (263-0) 257 (260-0) 225 (250-0) 273 (275-271) 254 (275-0) .1835
Mouth pain 225 (250-0) 220 (263-0) 220 (233-0) 288 (2100-275) 227 (2100 -0) .2057
Mouth sensitivity 221 (229-100) 225 (263-0) 238 (243-0) 243 (267-33) 225 (267-100) .6835
Duration of mouth-throat pain Median in weeks (range): WHO toxicity scale pain 8.0 (7.9-8.4) 8.0 (2.0-8.4) 8.0 (7.9-8.7) 6.4 (1.3-8.3) 8.0 (1.3-8.7) .5050












































Table 4. Response to Treatment: Pooling by Frequency of Mouthwash Use
Arms A+B
(Daily dose: 9 mg)
Arms C+D
(Daily dose: 6 mg)
P Value for Change
between A+B versus C+D
Number of patients N 5 9 N 5 9
Frequency of use X3/day X2/day
mOMRS at baseline
Mean (SD) 34.44 (13.15) 26.00 (7.11) .2315*
Median (range) 37 (21-63) 24 (20-44)
mOMRS at final visit
Mean (SD) 14.56 (8.78) 8.33 (5.24) .1015*
Median (range) 15 (2-32) 7 (2-17)
Relative reduction in mOMRS (%) ([final visit2baseline]/baseline)
Mean (SD) 255.5 (26.87) 268.45 (19.6) .4268*
Median (range) 248.7 (290.5-213.5) 272.7 (290.0-229.2)
P value for change between baseline and final visit .0001† <.0001†
mOMRS indicates modified oral mucosal rating scale; SD, standard deviation.
*Wilcoxon test, 2 sided.
†Paired t test, 1 sided.
Biol Blood Marrow Transplant 18:134-140, 2012 139Topical Budesonide for Oral cGVHDdetermined by the similarities between the pooled
groups at the beginning and end of the study (Table 4).
Evidence of the beneficial effect of budesonide
mouthwash was noticed when the pooled mOMRS
value at baseline was compared with the pooled
mOMRS value at the final visit (Table 4). These differ-
ences were statistically significant within both groups.Safety Evaluation
Eight of the 16 patients who suffered from adverse
events had events that were at least ‘‘possibly related’’
to the study drug. All of these adverse drug reactions
were mild (6 events) to moderate (2 events), including
gastrointestinal disorders (cheilitis, esophagitis), fun-
gal infection, and nervous system disorder (taste alter-
ation). Most of the previously mentioned adverse drug
reactions resolved with cessation of the study drug or
with basic antifungal treatment (6 events), although 1
adverse drug reaction did not resolve (fungal infection)
and 1 patient was lost to follow-up (taste alteration).
Three patients interrupted treatment because of ad-
verse events (1 patient in Arm B and 2 patients in
Arm D), and 2 of them discontinued participation in
the study (Arms B and D). One patient suffered from
3 serious adverse events that were not drug related
(Arm B) and did not interrupt the study protocol.
At visits 1, 4, and 5 (6.90 6 3.17, 6.65 6 2.26,
and 6.97 6 2.74 mg/dL, respectively), the average
serum cortisol concentrations were within the normal
range (5-25 mg/dL). At visits 2 and 3 (4.51 6 1.31 and
4.556 1.64 mg/dL), the serum cortisol concentrations
were slightly below normal range. The comparison
in mean serum cortisol concentrations between visits
1 to 5 did not show a significant difference between
the visits (P 5 .1108). The numbers of subjects in
the treatment groups (Arms A-D) were too small to
conclude any differences between treatment groups
regarding the serum cortisol concentrations (a total
of 10 patients).DISCUSSION
Four dosing protocols of a new topical budesonide
preparation were evaluated to determine which dosage
can achieve a reduction of at least 50% in the mOMRS
score (objective improvement) between the initial and
final visits of this 8-week trial. All patients showed
improvement, and 61% improved objectively. There
were no significant differences in response rate among
the 4 treatment arms. The other objective and subjec-
tive variables examined, which indicate oral cGVHD
severity, support the conclusion that this preparation
is beneficial, irrespective of the dosing protocol em-
ployed.
The dose of topical budesonide reported in the lit-
erature for treatment of oral cGVHD is higher than the
doses tested in this study. For example, 15-minutes
protocols 3 to 4 times daily were reported by Elad
et al. [10] and Sari et al. [19]. In a report describing 2
patients, a lower dose (3 mg of budesonide for 3-5 min-
utes 3 times daily) [20] was used. All studies regarding
topical budesonide had favorable results. Although
compliance was not an obstacle in our previous study
that had a 15-minutes, 3 times a day mouthwashing
schedule [10], in this study we reduced the duration
to 10 minutes, 2 or 3 times daily in order to make it
easier for the patients.
According to the literature, the benefits of topical
budesonide treatment increase over time, and the early
response within the first 2 to 3 weeks of treatment is
enhanced by cumulative effects during the next weeks
of treatment [10,19]. Our findings are congruent with
these publications, because the greatest improvement
was noted after 5 to 7 weeks of treatment. Therefore,
patients using topical budesonide should be informed
about the lag between treatment commencement and
response. The implications for future trials and
follow-up periods are clear.
Pharmacokinetic studies of budesonide in healthy
individuals showed that only 2% of a buccal dose of
140 Biol Blood Marrow Transplant 18:134-140, 2012S. Elad et al.budesonide enters the systemic circulation [11].
However, in patients with oral cGVHD, 10% of the
dose entered the circulation, possibly because of altered
drug uptake (because of the loss of epithelial integrity
in ulcerative lesions) andmetabolization [11]. This sys-
temic level is similar to the safe concentrations reached
after oral intake of enteric-coated budesonide for in-
flammatory bowel disease [21,22]. In our study, no
severe adverse events were attributed to topical
treatment with budesonide. The remaining adverse
events possibly associated with the study drug were
mainly mild, localized to the mouth and its
surrounding tissues, and transient. The absence of
adverse effects, together with steady serum cortisol
levels, confirms previous studies regarding the
safety profile of topical budesonide in oral cGVHD
patients [10,19,20].
In summary, this study was designed to determine
the best dosing protocol for a novel topical budesonide
formulation to be able to continue to the next stage of
drug development. We want to manage oral cGVHD
in a safe yet aggressive manner, and our safety analysis
supports a dosing schedule of 3 mg of budesonide 3
times a day applied for 10 minutes in the form of
a mouthwash. Currently, a large-scale, phase III, ran-
domized, controlled, double-blinded study is being
conducted in multiple centers to assess the efficacy of
this safe dose of the new preparation of topical budeso-
nide in the treatment of oral cGVHD (http://www.cli-
nicaltrials.gov identifier NCT00887263).ACKNOWLEDGMENTS
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